PGD: A Protein Involved in The Citric Acid Cycle and Cellular Signaling

Target Name: PGD

NCBI ID: G5226

Content of Review Report on PGD Target / Biomarker

PGD

PGD: A Protein Involved in The Citric Acid Cycle and Cellular Signaling

PGD 鈥嬧??(6-phosphogluconate dehydrogenase, decarboxylating (isoform 1)) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key enzyme in the citric acid cycle, also known as the Krebs cycle or tricarboxylic acid (TCA) cycle, which is a central metabolic pathway that generates energy in the form of ATP from glucose.

PGD 鈥嬧?媔s a 22-kDa protein that is localized to the endoplasmic reticulum (ER) and cytoplasm. It is involved in the citric acid cycle by catalyzing the conversion of 6-phosphogluconate to 5-phosphogluconate. This reaction is a key step in the citric acid cycle and is critical for the production of ATP energy.

PGD 鈥嬧?媓as also been shown to play a role in cellular signaling. It has been shown to be involved in the regulation of cell proliferation, cell death, and cell survival. Additionally, PGD has been shown to be involved in the regulation of inflammation and immune response.

As a drug target, PGD has been identified as a potential target for several diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. For example, studies have shown that inhibition of PGD has been shown to inhibit the growth of cancer cells and to protect against neurodegenerative diseases.

PGD 鈥嬧?媓as also been shown to be a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. For example, studies have shown that levels of PGD have been increased in cancer cells and have been associated with the development of cancer. Additionally, PGD has been shown to be decreased in the brains of individuals with neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

In addition to its potential as a drug target and biomarker, PGD is also of interest as a potential therapeutic approach. For example, inhibition of PGD has been shown to be effective in treating neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Additionally, PGD 鈥嬧?媓as also been shown to be potential target for cancer, where inhibition of its activity has been shown to be effective in treating several types of cancer.

In conclusion, PGD is a protein that is expressed in various tissues throughout the body and is involved in the citric acid cycle. It has also been shown to play a role in cellular signaling and has been identified as a potential drug target and biomarker for several diseases, including cancer and neurodegenerative diseases. Further research is needed to fully understand its role and potential as a therapeutic approach.

Protein Name: Phosphogluconate Dehydrogenase

Functions: Catalyzes the oxidative decarboxylation of 6-phosphogluconate to ribulose 5-phosphate and CO(2), with concomitant reduction of NADP to NADPH

The "PGD Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PGD comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets